In the BioHarmony Drug Report Database
Fetzima (levomilnacipran) is a small molecule pharmaceutical. Levomilnacipran was first approved as Fetzima on 2013-07-25. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter. In addition, it is known to target sodium-dependent dopamine transporter. Fetzima’s patents are valid until 2032-05-23 (FDA).
Image (chem structure or protein)